Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Phase1 Ind Navigator topic
No spam. Unsubscribe anytime.
FDA highlights Phase 1 IND navigator to help smaller developers
Summary
FDA officials described a new Phase 1 IND navigator website and a dedicated contact point intended to centralize guidance, CMC flexibilities, and training resources for sponsors, especially smaller companies and academic investigators preparing INDs.
Mike Davis said the agency is launching a Phase 1 IND navigator website to centralize key guidance and reduce confusion about requirements for early‑stage INDs. "The navigator is intended to serve as a centralized starting point for drug and biologic developers preparing an IND and planning early clinical development," he said, adding the resource includes guidance documents, learning resources and applicable CFR provisions.
Officials said the navigator is not a substitute for product‑specific scientific judgment or formal interactions with the review division, but is intended to help smaller companies and academic investigators identify relevant materials earlier and prepare higher‑quality submissions. The agency also noted a dedicated phone and email contact for Phase 1 questions will be available to help developers find the right points of contact.
